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Abstract
Neurological disorders (NDs) are diseases of the central and peripheral nervous 
system that affected the hundreds of millions of people worldwide. Temporal lobe 
epilepsy (TLE) is a common NDs with hallucinations and disturbance of consciousness 
that cause the abnormal neurological activity in any part of brain. Neuroinflammation 
(NI) has been identified in epilepsy-related tissue from both experimental and clinical 
evidence and suspected to participate in the formation of neuronal cell death, reactive 
gliosis and neuroplastic changes in the hippocampus, may contribute to epileptogen-
esis. The NI is tightly regulated by microglia, but it is thought that excessive or chronic 
microglial activation can contribute to neurodegenerative processes. Therefore, the 
modulation of microglia responses may provide a therapeutic target for the treatment 
of severe or chronic NI conditions. Although the condition responds well to antiepi-
leptic drugs (AEDs), there are still unresponsive to AEDs in about 1/3 of cases. Neural 
stem cells are the origin of various types of neural cells during embryonic development. 
Currently, many results of stem cell therapies in the animal experiments and clinical 
trials were demonstrated the efficacious therapeutic effects in the attenuated symp-
toms of ND. Therefore, the combined application therapies of stem cells and drugs may 
be a promising  candidate for the therapeutic strategies of NDs, especially TLE.
Keywords: combined application therapies, stem cells, drugs, neurological disorder 
attenuation
1. Neurological disorders in people
When the disorders occurred in the brain and spinal cord included cranial 
nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular 
junction, and muscles, etc., these disorders were named neurological disorders 
(NDs). NDs are complicated and that are caused by a loss of neurons and glial cells 
in these injured areas in brain or spinal cord. NDs include epilepsy, Alzheimer’s 
disease, Parkinson’s disease (Figure 1), dementias, cerebrovascular diseases 
(stroke, migraine, and headache disorders, etc), multiple sclerosis, neuro-infected 
disorders, brain cancer-caused disorders, head trauma-caused traumatic  nervous 
 disorders, and malnutrition-induced NDs. Currently, NDs can affect about hun-
dreds of millions of people worldwide. Among NDs, more than 50 million people 
have epilepsy worldwide [1].
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2. Epilepsy
Approximately 1–3% of the worldwide population suffers from epilepsy. 
Pharmacotherapy represents the mainstay of treatment for most of the patient 
population. Moreover, surgery is another option for patients in whom a defined 
resectable seizure focus can be identified by brain imaging and seizure mapping 
techniques. For patients whose seizures cannot be controlled by antiepileptic drugs 
(AEDs) or not viable for surgery, vagal nerve stimulation will be a third possible 
option [2]. Unfortunately, there are a significant number of patients with epilepsy 
continue to live with uncontrolled seizures. Therefore, there is a clear need for more 
efficacious therapies for these epileptic patients with uncontrolled seizures. In order 
to identify an efficient therapy for preventing epileptogenesis, a validated animal 
model is required for translating discoveries at the molecular and genetic basis of 
epilepsy [3].
3. Neuroinflammation causes of epilepsy
Neuroinflammation is an underlying component of a diverse range of 
neurodegenerative diseases and their associated neuropathology, and increasing 
evidence suggests that microglia are a key causative factor in this process. Microglia 
comprised approximately 12% of cells in the brain [2]. They predominate in the 
gray matter especially in the hippocampus, olfactory telencephalon, basal ganglia, 
and substantia nigra. Commonly, microglia are readily activated in response to 
brain injury or immunological stimuli. Over-activated microglia can induce highly 
detrimental neurocytotoxic factors such as superoxide, nitric oxide (NO), and 
proinflammatory cytokines (IL-1β, IL-6, and TNF-α, etc.). In status epilepticus 
(SE), activated microglia have been shown to be present microgliosis [2, 3]. 
At present, many evidences have demonstrated rapid astrocyte and microglial 
activation following pilocarpine-induced seizures or SE. However, whether 
pilocarpine directly activate microglia is poorly understood.
Figure 1. 
Parkinson’s disease model. Mice were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by 
intraperitoneal injection once per day for continuous 5 days to induce Parkinson’s disease ①. The experimental 
process of Parkinson’s disease was described ②. ③ was the experimental end point.
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4. Treatments of epilepsy
SE is a major neurologic emergency which is characterized by continuous 
seizures lasting greater than 5 minutes, and SE generation may increase the mortal-
ity and morbidity in patients [4–6]. The mechanism of SE generation is believed 
to correlate with the increase of excitatory activity and/or the decrease of inhibi-
tory activity in the brain [7, 8]. Treatments can help epileptic patients to decrease 
seizures or stop seizures. These therapeutic treatments include medicines (anti-
epileptic drugs, AEDs), surgery, special diet (ketogenic diet), and electrical device 
therapy, etc. Traditionally, the strategies of SE treatment included the augmented 
inhibitory neurotransmission and/or reduced excitatory neurotransmission by 
pharmaceutical administration, but the clinically AEDs still fail to control the 
seizures in approximately 20–40% of SE patients [9–13]. Moreover, the underlying 
mechanisms of AEDs-resistant SE are still unclear, and it is important to figure 
out the response of pharmaco-resistance in intact brain for the development of 
 promising treatment.
5. Characteristics, types, and therapy of stem cells
The treatment of epilepsy is not cured for a long time, and frequent seizures 
have brought endless troubles to the majority of patients. Nowadays, the treat-
ment of epilepsy is no longer a medical problem, and can finally be completely 
ended. Only because of the advent of stem cell transplantation therapy, an indel-
ible milestone has been set for the treatment of epilepsy. Stem cell transplantation 
technology has brought good news to patients with epilepsy, and has achieved a 
major new medical breakthrough in the treatment of epilepsy. Stem cell treatment 
of epilepsy is to inject healthy and young stem cells (SCs) into the patient’s body 
through intravenous injection to replace their diseased or aging tissues and organs 
for the purpose of treating epilepsy.
Whether stem cell therapy effective for these epileptic patients who are not well 
treated by surgery? What is the principle? Stem cell transplantation increases the 
number of neurons In fact, it mainly uses the differentiation function of neural 
stem cells. Neural stem cells (NSCs) can divide and differentiate into corresponding 
cell types in the brain according to the induction of their surrounding microen-
vironment. Their morphology and function are very similar to those of nearby 
host cells, and they have a certain degree of safety. However, for drug-resistant 
intractable epilepsy, especially the effect of temporal lobe epilepsy (TLE) is better. 
TLE is caused by the degeneration, necrosis, and decrease in the number of hip-
pocampal neurons, which leads to a decrease in the inhibitory neurotransmitter 
γ-aminobutyric acid. However, stem cell transplantation can repair and increase 
the number of γ-aminobutyric acid neurons. Therefore, restoring the balance of 
inhibitory neurotransmitters and excitatory neurotransmitters may fundamentally 
cure TLE.
The principle of cell therapy is easily described as your own cells as “autologous 
cells” or other people’s cells as “allogeneic cells”. After in vitro culture or processing 
procedures, these treated cells are introduced into the patient’s body for apply to 
achieve the purpose of treating or preventing diseases [14].
SCs can build every tissue in the human body, there they have great potential 
for therapeutic applications in tissue regeneration and repair. SCs can differentiate 
into specific cell types. SCs’ characteristics are the perpetual self-renewal and the 
differentiation ability to become a specialized adult cell type. Currently, two major 
classes of SCs are pluripotent SCs (PSCs) and multipotent SCs (MSCs) [14].
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PSCs can differentiate into any cell in the adult body and it also was named “embry-
onic stem cells”. Recently, “induced PSCs” (iPSCs), with some of the same PSCs’ char-
acteristics as proliferation, morphology and gene expression were yielded adult cells 
back into the pluripotent state via applying the molecular manipulation (added Klf4, 
c-Myc4, Lin28, and Nanog). Unfortunately, these iPSCs via genetic engineering are not 
likely approved for human disease therapy. Consequently, the results of a purely chemi-
cal approach to deliver safer transcription genes into the cells look promising [14].
MSCs are only restricted to differentiate a limited cell population. MSCs were 
found in bone marrow and have been used therapeutically since the 1960s. Recently, 
the new sources for MSCs such as the placenta, heart, umbilical cord blood, and 
brain were found. In the brain, neuro-progenitor cells have differentiated abilities to 
become neural cells. MSCs may have a potential for clinical application. MSCs have 
the plasticity to become all the progenitor cells or become only one or two special-
ized cell types of a particular tissue [14]. Based on our in vivo model, the results of 
SCs therapy in the epileptic research have some progress (Figure 2).
SCs can develop into cells of different specialized cell types in the body and grow 
into new body tissues. For example as transformation into different body cell types, 
including muscle cells, nerve cells, and blood cells. SCs have the potential to treat 
many diseases, including stroke, heart attack, spinal cord injury, and macular degen-
eration, etc. Whether SCs be used to treat epilepsy? Since most cases of epilepsy can 
be attributed to differences in receptor expression in the brain (due to mutations), 
theoretically correcting these may reduce the likelihood of electrical seizures in the 
brain. In addition, during status epilepticus, excitatory overload sometimes kills neu-
rons, especially neurons in the hippocampus. Over time, this actually worsens the 
condition and leads to the development of temporal lobe epilepsy (TLE). Although 
AEDs can treat seizures, the damage to the temporal lobe is usually irreversible and 
permanent, and current treatments do not solve this problem [15–17].
Figure 2. 
Pilocarpine-induced status epilepticus model. Mice were firstly pretreated with scopolamine by intraperitoneal 
injection for 30 min before the induction of SE. Later, pilocarpine was administrated via intraperitoneal 
injection. Two hours after SE onset, mice were treated intraperitoneally with diazepam to terminate seizures. 
The process of status epilepticus was described as ① + ②. After one day post pilocarpine induction, stem cell 
therapy was performed until the experimental end point ③.
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The scientific research of SCs in the treatment of epilepsy were showed as (1) PSCs 
transplantation to treat TLE: Human induced pluripotent stem cells (hiPSCs) are 
induced to develop into any type of cells in the body, including GABAergic interneu-
rons. According to literatures, GABAergic interneuron progenitor cells derived from 
hiPSC were transplanted into the hippocampus of a TLE model to observe its efficacy. 
The results were presented that medial ganglion cells (MGE) derived from hiPSCs 
after the cell transplantation into the hippocampus. Later, researchers successfully 
reduced the frequency of seizures and reduced the loss of GABAergic neurons. (2) SCs 
were obtained from the patient’s own bone marrow to treat TLE: the use of autologous 
mesenchymal stem cells in patients with epilepsy can reduce overall seizure frequency. 
SCs are obtained from the patient’s own bone marrow and intravenously administered 
into the spinal cord. One year later, 30% epilepsy patients had a complete remission 
(without seizures), and 50% epilepsy patients who had not previously responded to 
the medication began to respond well [18–20].
6. Anti-epileptic candidate drugs
During neuro-inflammation, the pro-inflammatory cytokines as 
interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha 
(TNF-α) produced by activated microglia or astrocytes provoke pathological 
signaling cascades through the activation of phospholipase C and phospholipase 
A2. Later, the release of non-esterified arachidonic acid (AA) from phospholipids 
and the formation of lysophospholipids and bioactive eicosanoids by oxidized 
enzymes. Three enzyme systems, cyclooxygenases, lipoxygenases, and cyto-
chrome P450 (CYP) epoxygenases metabolize released AA to lipid metabolites as 
prostaglandins, leukotrienes, and epoxyeicosatrienoic acids (EETs), respectively. 
Brain parenchymal tissue metabolizes AA to EETs via the CYP epoxygenase, 
which regulate cerebral blood flow and perform anti-inflammatory and anti-
apoptotic effects. Previous results were showed that hypoxia and ischemic 
preconditioning experiments have shown that the increased expression of CYP 
epoxygenase and EETs in brain may confer protection from ischemic stroke 
induction. EETs signaling may play a role in suppressing the ischemia-evoked 
inflammatory cytokine responses in the brain circulation. Soluble epoxide hydro-
lase (sEH) is a key enzyme for metabolic conversion of EETs into their less active 
form, dihydroxyeicosatrienoic acids. The inhibition of sEH has been used to 
increase systemic EETs level and bioactivity. By using pharmacologic inhibitor or 
genetic deletion, the inhibition of sEH attenuated the vascular and neural injury 
induced by cerebral ischemia, suggesting sEH might be a novel target in treatment 
of stroke. In response to these findings, we hypothesized that sEH is involved in 
neuroinflammation-related epileptogenesis [21].
The sEH enzyme has thus been identified as a therapeutic target for inflamma-
tion, and therefore might serve to treat inflammatory pain [21]. Previous studies 
shown that during peripheral inflammatory, pain GABA A receptor mediated syn-
aptic inhibition was enhanced in neurons [22]. Inhibition of sEH may have elevated 
the GABA agonists levels and enhance spinal GABAergic transmission [22]. In this 
context, the basis of kindling-induced epileptogenesis has been hypothesized that 
enhanced and/or attenuated activation in pathways utilizing glutamate and GABA 
as the neurotransmitter, respectively [22]. The sEH enzyme may influence the 
balance between neuronal excitation and inhibition, where glutamate and GABA, 
respectively, play important roles, and alter the seizure-induction threshold.
sEH is a member of the α/β-hydrolase fold family of enzymes which has two 
domains: a C-terminal epoxide hydrolase domain (EH), which is responsible for 
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the biological roles associated with sEH and an N-terminal lipid phosphatase 
domain (PT) connected by a proline rich linker [23]. The role of sEH in lipid 
metabolism and lipid related disorders have been emerged in the recent years. sEH 
and dyslipidemia and related disorders such as atherosclerosis and coronary heart 
disease were related [24]. The products of the sEH hydrolase domain including fatty 
acid epoxide substrates and diol were found to activate PPARs, which can modulate 
plasma lipid by regulating lipid metabolism [24]. Moreover, the hydrolase domain 
of sEH are shown the effect on lowering cholesterol level by reducing the HMG-
CoA reductase expression. However, the phosphatase domain of sEH was shown 
to regulate the cholesterol biosynthesis pathway by hydrolyzing the isoprenoid 
intermediates which are involved in cholesterol metabolism [24]. Summarily, the 
hydrolase and phosphatase domains of sEH exhibit opposite effects on expression 
of cholesterol levels. According the context about the opposite effects of sEH C- and 
N-terminal domain on regulating the cholesterol expression, we hypothesize that 
the sEH C-terminal domain may play a seizure-induction role and the N-terminal of 
sEH may be a seizure-protection role. In the previous studies, the pharmacokinetic 
parameters of sEH C-terminal inhibitor, AUDA [12-(3-adamantan-1-yl-ureido)-
dodecanoic acid] in brain tissue samples were the mean residence time of 6 h and 
half-time elimination of 4 h [24].
7. Pilocarpine-induced SE models in vivo and in vitro
A pilocarpine-induced SE model is wildly used to investigate the alteration of 
neuronal circuits which reproduced most of the epileptic characteristics in patients. 
In the pilocarpine-induced SE model, acute SE is successfully induced in only a 
subset of rats after the high-dose pilocarpine injection [25]. According to our previ-
ous epileptic mouse model, mice were firstly pretreated with scopolamine methyl 
nitrate (1 mg/kg BW, Sigma-Aldrich) by intraperitoneal injection for 30 min before 
the induction of SE. Later, 325 mg/kg body weight (BW) pilocarpine hydrochloride 
was administrated via intraperitoneal injection. Mouse behaviors were monitored 
and scored according to Racine’s scale (Table 1) [24–26]. Two hours after SE onset, 
mice were treated intraperitoneally with 10 mg/kg BW diazepam to terminate 
seizures (Figure 3).
In vivo seizure models are important for the research of epilepsy and seizure 
activity. Currently, in vitro models for epileptic research included rodent brain 
tissue slices and central nervous system (CNS) cell cultures [26]. These in vitro 
models have been performed for the research of epileptic mechanisms. The status 
of “seizure” and “seizure-like” were described in the in vivo and in vitro epileptic 
Class (seizure stage) Racine’s scale behavioral expression
1 Mouth and focal movement
2 Head nodding
3 Contralateral forelimb clonus
4 Symmetrical forelimb clonus with rearing
5 Rearing and falling
Table 1. 
Five class of Racine’s scale for seizure stage.
7
Combined Application Therapies of Stem Cells and Drugs in the Neurological Disorder…
DOI: http://dx.doi.org/10.5772/intechopen.94484
studies, respectively [27, 28]. In vitro CNS cell models were established by applying 
12-(3-Adamantan-1-yl-ureido)-dodecanoic acid (AUDA) that was ordered from 
Cayman Chemical (Ann Arbor, MI, USA) and dissolved in dimethyl sulfoxide 
(DMSO; Cat No. 472301; Sigma-Aldrich, MO, USA). Cells were obtained as mouse 
retroviral immortalized microglia BV-2 cells belonged to C57BL/6 background (a 
gift from Dr. Hsiao-Li Chuang, National laboratory animal center, Taipei, Taiwan). 
They were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/
ml streptomycin in 5% CO2 atmosphere at 37°C. Cells were grown to 90% conflu-
ency before experiments. Later, cells were treated with 100 μM pilocarpine and/
or 100 μM AUDA and cultured for 24 hr. in 10% FBS-DMEM on glass coverslips 
and performed the observation of BV-2 cell morphology by light microscope. Cell 
viability was measured by MTT assay according to the manufacturer’s instructions 
(MERCK, Darmstadt, Germany). In vitro scratch wounding-healing assay was 
performed as described. Briefly, confluent BV-2 microglia in 6-well plates were 
washed with serum-free DMEM three times. A line down the center of each well 
was scraped with a p200 pipette tip, followed by a wash to remove debris with 
serum-free DMEM. Images were taken at 10× magnification, scratch widths were 
measured, and wound closure was calculated by dividing widths measured after 
a 8 hr. incubation by the initial scraped width. Each experiment was carried out 
in triplicate and three fields were counted per well by scorers blinded to experi-
mental conditions. Boyden chamber assays were performed in the transwells (BD 
Bioscience, New Bedford, MA) as previously described. BV-2 microglia (4 × 104 cells 
in 200 μL of serum-free DMEM) were added to the upper chamber and allowed to 
adhere to the polycarbonate filters (8 μm pore) for 30 min at 37°C in a humidified 
Figure 3. 
Pilocarpine-induced status epilepticus model. Mice were firstly pretreated with scopolamine by intraperitoneal 
injection for 30 min before the induction of SE. Later, pilocarpine was administrated via intraperitoneal 
injection. Two hours after SE onset, mice were treated intraperitoneally with diazepam to terminate seizures. 
The process of status epilepticus was described as ① + ②. After one day post pilocarpine induction, drug 
therapy was performed until the experimental end point ③.
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atmosphere of 95% air and 5% CO2. Following, cells were pretreated with 100 μM 
pilocarpine at 37°C for 30 min prior to AUDA treatment. 100 μM AUDA were then 
placed in the upper chamber and lower chamber was added with 10% FBS-DMEM 
to allowed cell migration. Cells did not migrate and remained on the upper surface 
of the filter were removed. Cells had migrated to the lower surface were stained 
with Liu’s stain (ASK, Taoyuan, Taiwan) and counted under light microscope. In 
at least three independent experiments, three wells per treatment were counted in 
nine random fields at 40× magnification per well by scorers blind to experimental 
conditions.
8.  AUDA is safe in in vivo study and significantly inhibited pilocarpine-
induced BV-2 microglial viability and migration in vitro
In the acute toxic assay in vivo, high doses of AUDA (100, 200, and 300 mg/kg 
BW) were respectively administrated for mice (n = 6/dose), all mice were survival 
and their clinical symptoms were normal. The results of AUDA were verified safe. 
Non-cytotoxic concentration (100 μM) of pilocarpine and AUDA were used in this 
study. Non-cytotoxic effect was presented after 100 μM pilocarpine combined with 
100 μM AUDA treatment. According to our studies, AUDA significantly suppressed 
cell migration compared to the control by using respectively in vitro scratch wound-
healing assay and Boyden chamber assay (p < 0.001) (Figures 4 and 5). According 
to these results, AUDA had the ability for the inhibition of the C-terminal domain 
of sEH can suppress the seizure development. C-terminal domain of sEH may play 
an important role in the epileptogenesis.
Figure 4. 
In vitro scratch wound-healing assay. Non-cytotoxic concentration (100 μM) of pilocarpine and AUDA were 
used in this study. 100 μM pilocarpine was first treated to BV-2 cells before 100 μM AUDA treatment. Later, 
AUDA treatment for 7.5 hours until the experimental end.
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Figure 5. 
Boyden chamber assay. Pilocarpine (100 μM) and AUDA (100 μM) were used in this study. Pilocarpine was first 
treated to BV-2 cells before AUDA treatment. Later, AUDA treatment for 7.5 hours until the experimental end.
Figure 6. 
Amendments to the administrative measures for the implementation or use of specific medical technology 
inspection and testing medical instruments in Taiwan in 2018. The six major projects can be divided into two 
categories: “Disease therapy” and “tissue repair”. The two peripheral blood stem cells and immune cells are 
mostly used to treat cancer. The other four cell types belong to regenerative medicine, with the goal of helping 
tissue regeneration or repair.
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9.  Amendments to the administrative measures for the implementation 
or use of specific medical technology inspection and testing medical 
instruments in Taiwan
Cell replacement therapy and gene transfer to the diseased or injured brain have 
provided the basis for the development of potentially powerful new therapeutic 
strategies for a broad spectrum of human neurological diseases. However, the 
paucity of suitable cell types for cell replacement therapy in patients suffering 
from neurological disorders has hampered the development of this promising 
therapeutic approach. The full name of the “Special Control Law” issued by the 
Ministry of Health Services is “Administrative Measures for the Implementation or 
Use of Medical Instruments for Special Medical Technical Inspections”, which was 
officially announced on September 6, 2018. The six major projects may seem com-
plicated, but in terms of teleology, they can be divided into two categories: “disease 
therapy” and “tissue repair”. The two peripheral blood stem cells and immune cells 
are mostly used to treat cancer. The other four cell types belong to regenerative 
medicine, with the goal of helping tissue regeneration or repair (Figure 6).
10. Conclusions
Currently, cell sources, characteristics, differentiation and therapeutic strategies 
and applications are frequently discussed worldwide. SCs have great potential in 
the regeneration and repair of tissue in people. However, limited information were 
presented at present. Therefore, the deeper studies will be still needs to be learned 
about their biology, manipulation and safety before their full therapeutic potential 
can be achieved. SCs-based therapies have shown encouraging results in treating 
diseases including epilepsy. Experimental animal and clinical studies have shown 
that SCs have significant regenerative properties on epileptic animal and patients 
with epilepsy. However, before SCs therapy becomes routine, larger clinical trials 
are needed [29–31]. In addition, our previous studies suggested that sEH played a 
Figure 7. 
Combined application therapies of stem cells and drugs in the neurological disorder attenuation. Based 
on epilepsy, some symptoms were increase as spontaneous seizure, mossy fiber sprouting, brain edema, 
hippocampal volume, GABAergic interneuron number, astrocyte activity, microglia activity. However, neuron 
number was decrease. After the combined application therapies of stem cells and drugs in the neurological 
disorder, the above symptoms were reversed.
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critical role in regulating epileptogenesis in the pilocarpine-induced SE mice and 
in vitro CNS cell platform. Blocking of C-terminal activity of sEH via AUDA treat-
ment can attenuate significantly epileptogenesis. Blocking of C-terminal activity of 
sEH on epileptogenesis may be provided a novel therapeutic approach in epilepsy. 
Anti-functional sEH C-terminal domain also may be a potential biomarker therapy 
for epileptogenesis in the future. Finally, the combined application therapies of SCs 
and drugs as AUDA may be try to apply in attenuating NDs (Figure 7).
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